-
公开(公告)号:US20210317161A1
公开(公告)日:2021-10-14
申请号:US15536292
申请日:2015-12-14
申请人: Agasaladinni NAGANA GOUD , Shafee MOHAMMED ABDUL , Vadlamani SURESH KUMAR , Dagadu PATIL NILESH , Koppala MOHAN RAO , AURO PEPTIDES LTD
发明人: Nagana Goud Agasaladinni , Mohammed Abdul Shafee , Suresh Kumar Vadlamani , Patil Nilesh Dagadu , Mohan Rao Koppala
IPC分类号: C07K1/06 , C07K14/655
摘要: The present invention relates to a process for the preparation of Pasireotide of formula (I) and its acid addition salts. More particularly the present invention is directed to a process for the synthesis of Pasireotide of formula (I) having purity greater than 99.0% by HPLC using fragment coupling.
-
公开(公告)号:US20180251511A1
公开(公告)日:2018-09-06
申请号:US15523384
申请日:2015-10-31
申请人: Vadlamami SURESH KUMAR , Dagadu PATIL NILESH , Shafee MOHAMMED ABDUL , Patil SANJAY DEVIDAS , Agasaladinni NAGANAGOUD , AURO PEPTIDES LTD
发明人: Suresh Kumar Vadlamani , Patil Nilesh Dagadu , Mohammed Abdul Shafee , Sanjay Devidas Patil , Nagana Goud Agasaladinni
IPC分类号: C07K14/605
CPC分类号: C07K14/605
摘要: The present invention relates to a process for the preparation of Liraglutide, which comprises: a) synthesis of suitable fragments (protected) by solid phase peptide synthesis; b) coupling of the suitable fragments on solid support; c) concurrently cleaving the protected peptide from the solid support and de-protecting the peptide; d) purification of Liraglutide (crude) on reverse phase HPLC; e) isolating pure Liraglutide.
-
公开(公告)号:US10344069B2
公开(公告)日:2019-07-09
申请号:US15523384
申请日:2015-10-31
申请人: Auro Peptides Ltd , Suresh Kumar Vadlamani , Patil Nilesh Dagadu , Mohammed Abdul Shafee , Sanjay Devidas Patil , Nagana Goud Agasaladinni
发明人: Suresh Kumar Vadlamani , Patil Nilesh Dagadu , Mohammed Abdul Shafee , Sanjay Devidas Patil , Nagana Goud Agasaladinni
IPC分类号: C07K14/605
摘要: The present invention relates to a process for the preparation of Liraglutide, which comprises: a) synthesis of suitable fragments (protected) by solid phase peptide synthesis; b) coupling of the suitable fragments on solid support; c) concurrently cleaving the protected peptide from the solid support and de-protecting the peptide; d) purification of Liraglutide (crude) on reverse phase HPLC; e) isolating pure Liraglutide.
-
-